Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2013

01-12-2013 | Review Article

Heavy chain deposition disease: an overview

Authors: Yuji Oe, Jun Soma, Hiroshi Sato, Sadayoshi Ito

Published in: Clinical and Experimental Nephrology | Issue 6/2013

Login to get access

Abstract

Heavy chain deposition disease (HCDD) is one of three entities of monoclonal immunoglobulin deposition disease, characterized histopathologically by the presence of nodular glomerulosclerosis and glomerular and tubular deposition of monoclonal heavy chains without associated light chains. Although HCDD is an extremely rare disease, >30 cases have been reported to date in the literature. Of these cases, only three cases have been reported in Japan. The majority of the patients presents with nephrotic syndrome, hematuria, and hypertension, and develop progressive renal failure with or without the complication of multiple myeloma. Some cases have been treated successfully using chemotherapy. Because of its rarity, a thorough understanding of HCDD is essential for both accurate diagnosis and adequate subsequent treatment.
Literature
1.
go back to reference Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidosis, Waldenström macroglobulinemia, and cryoglobulinemic nephropathies. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 853–910. Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidosis, Waldenström macroglobulinemia, and cryoglobulinemic nephropathies. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 853–910.
2.
go back to reference Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D’Agati VD. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.PubMed Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D’Agati VD. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.PubMed
3.
go back to reference Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, Leung N. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231–9.PubMedCrossRef Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, Leung N. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7:231–9.PubMedCrossRef
4.
go back to reference Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preud’homme JL. Brief report: heavy-chain deposition disease. N Engl J Med. 1993;329:1389–93.PubMedCrossRef Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preud’homme JL. Brief report: heavy-chain deposition disease. N Engl J Med. 1993;329:1389–93.PubMedCrossRef
5.
go back to reference Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking CH1. J Am Soc Nephrol. 1999;10:519–28.PubMed Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking CH1. J Am Soc Nephrol. 1999;10:519–28.PubMed
6.
go back to reference Tubbs RR, Berkley V, Valenzuela R, McMahon JT, Gephardt GN, Fishleder AJ, Nally JV, Pohl MA, Bukowski RM, Lichtin AE. Pseudo-gamma heavy chain (IgG4 lambda) deposition disease. Mod Pathol. 1992;5:185–90.PubMed Tubbs RR, Berkley V, Valenzuela R, McMahon JT, Gephardt GN, Fishleder AJ, Nally JV, Pohl MA, Bukowski RM, Lichtin AE. Pseudo-gamma heavy chain (IgG4 lambda) deposition disease. Mod Pathol. 1992;5:185–90.PubMed
7.
go back to reference Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas A, Aucouturier P. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis. 2004;43:E10–6.PubMedCrossRef Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas A, Aucouturier P. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis. 2004;43:E10–6.PubMedCrossRef
8.
go back to reference Oe Y, Nakaya I, Yahata M, Sakuma T, Sato H, Soma J. A case of γ1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy. Intern Med. 2010;49:1411–5.PubMedCrossRef Oe Y, Nakaya I, Yahata M, Sakuma T, Sato H, Soma J. A case of γ1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy. Intern Med. 2010;49:1411–5.PubMedCrossRef
9.
go back to reference Yasuda T, Fujita K, Imai H, Morita K, Nakamoto Y, Miura AB. Gamma-heavy chain deposition disease showing nodular glomerulosclerosis. Clin Nephrol. 1995;44:394–9.PubMed Yasuda T, Fujita K, Imai H, Morita K, Nakamoto Y, Miura AB. Gamma-heavy chain deposition disease showing nodular glomerulosclerosis. Clin Nephrol. 1995;44:394–9.PubMed
10.
go back to reference Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D’Agati VD. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33:954–62.PubMedCrossRef Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D’Agati VD. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33:954–62.PubMedCrossRef
11.
go back to reference Katz A, Zent R, Bargman JM. IgG heavy-chain deposition disease. Mod Pathol. 1994;7:874–8.PubMed Katz A, Zent R, Bargman JM. IgG heavy-chain deposition disease. Mod Pathol. 1994;7:874–8.PubMed
12.
go back to reference Herzenberg AM, Lien J, Magil AB. Monoclonal heavy chain (immunoglobulin G3) deposition disease: report of a case. Am J Kidney Dis. 1996;28:128–31.PubMedCrossRef Herzenberg AM, Lien J, Magil AB. Monoclonal heavy chain (immunoglobulin G3) deposition disease: report of a case. Am J Kidney Dis. 1996;28:128–31.PubMedCrossRef
13.
go back to reference Rott T, Vizjak A, Lindic J, Hvala A, Perkovic T, Cernelc P. IgG heavy-chain deposition disease affecting kidney, skin, and skeletal muscle. Nephrol Dial Transplant. 1998;13:1825–8.PubMedCrossRef Rott T, Vizjak A, Lindic J, Hvala A, Perkovic T, Cernelc P. IgG heavy-chain deposition disease affecting kidney, skin, and skeletal muscle. Nephrol Dial Transplant. 1998;13:1825–8.PubMedCrossRef
14.
go back to reference Herzenberg AM, Kiaii M, Magil AB. Heavy chain deposition disease: recurrence in a renal transplant and report of IgG2 subtype. Am J Kidney Dis. 2000;35:E25.PubMedCrossRef Herzenberg AM, Kiaii M, Magil AB. Heavy chain deposition disease: recurrence in a renal transplant and report of IgG2 subtype. Am J Kidney Dis. 2000;35:E25.PubMedCrossRef
15.
go back to reference Tan S, Pon K, Bargman J, Ghazarian D. Generalized cutis laxa associated with heavy chain deposition disease. J Cutan Med Surg. 2003;7:390–4.PubMedCrossRef Tan S, Pon K, Bargman J, Ghazarian D. Generalized cutis laxa associated with heavy chain deposition disease. J Cutan Med Surg. 2003;7:390–4.PubMedCrossRef
16.
go back to reference Vedder AC, Weening JJ, Krediet RT. Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. Nephrol Dial Transplant. 2004;19:1302–4.PubMedCrossRef Vedder AC, Weening JJ, Krediet RT. Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. Nephrol Dial Transplant. 2004;19:1302–4.PubMedCrossRef
17.
go back to reference Harrington CR, Beswick TC, Susa JS, Pandya AG. Acquired cutis laxa associated with heavy chain deposition disease. J Am Acad Dermatol. 2008;59(5 Suppl):S99–101.PubMedCrossRef Harrington CR, Beswick TC, Susa JS, Pandya AG. Acquired cutis laxa associated with heavy chain deposition disease. J Am Acad Dermatol. 2008;59(5 Suppl):S99–101.PubMedCrossRef
18.
go back to reference Cheng IK, Ho SK, Chan DT, Ng WK, Chan KW. Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin alpha heavy chain deposition. Am J Kidney Dis. 1996;28:283–8.PubMedCrossRef Cheng IK, Ho SK, Chan DT, Ng WK, Chan KW. Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin alpha heavy chain deposition. Am J Kidney Dis. 1996;28:283–8.PubMedCrossRef
19.
go back to reference Alexander MP, Nasr SH, Watson DC, Méndez GP, Rennke HG. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature. Am J Kidney Dis. 2011;58:621–5.PubMedCrossRef Alexander MP, Nasr SH, Watson DC, Méndez GP, Rennke HG. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature. Am J Kidney Dis. 2011;58:621–5.PubMedCrossRef
20.
go back to reference Liapis H, Papadakis I, Nakopoulou L. Nodular glomerulosclerosis secondary to mu heavy chain deposits. Hum Pathol. 2000;31:122–5.PubMedCrossRef Liapis H, Papadakis I, Nakopoulou L. Nodular glomerulosclerosis secondary to mu heavy chain deposits. Hum Pathol. 2000;31:122–5.PubMedCrossRef
21.
go back to reference Schroeder HW Jr, Torres RM. B-cell antigen receptor genes, gene products and coreceptors. In: Rich RR, Shearer WT, Kotzin BL, Schroeder HW Jr, editors. Clinical Immunology, principles and practice. 2nd ed. London: Mosby; 2001. p. 1.4.1–1.4.18. Schroeder HW Jr, Torres RM. B-cell antigen receptor genes, gene products and coreceptors. In: Rich RR, Shearer WT, Kotzin BL, Schroeder HW Jr, editors. Clinical Immunology, principles and practice. 2nd ed. London: Mosby; 2001. p. 1.4.1–1.4.18.
22.
23.
go back to reference Hendershot L, Bole D, Köhler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987;104:761–7.PubMedCrossRef Hendershot L, Bole D, Köhler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987;104:761–7.PubMedCrossRef
24.
go back to reference Cogné M, Silvain C, Khamlichi AA, Preud’homme JL. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood. 1992;79:2181–95.PubMed Cogné M, Silvain C, Khamlichi AA, Preud’homme JL. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood. 1992;79:2181–95.PubMed
25.
go back to reference Khamlichi AA, Aucouturier P, Preud’homme JL, Cogné M. Structure of abnormal heavy chains in human heavy-chain-deposition disease. Eur J Biochem. 1995;229:54–60.PubMedCrossRef Khamlichi AA, Aucouturier P, Preud’homme JL, Cogné M. Structure of abnormal heavy chains in human heavy-chain-deposition disease. Eur J Biochem. 1995;229:54–60.PubMedCrossRef
26.
go back to reference Tao MH, Smith RLF, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661–7.PubMedCrossRef Tao MH, Smith RLF, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661–7.PubMedCrossRef
27.
go back to reference Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989;143:2594–601. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989;143:2594–601.
28.
29.
go back to reference Shohet JM, Pemberton P, Carrol MC. Identification of a major binding site for complement C3 in the IgG1 heavy chain. J Biol Chem. 1993;268:5866–71.PubMed Shohet JM, Pemberton P, Carrol MC. Identification of a major binding site for complement C3 in the IgG1 heavy chain. J Biol Chem. 1993;268:5866–71.PubMed
30.
go back to reference Soma J, Tsuchiya Y, Sakuma T, Sato H. Clinical remission and histopathological resolution of nodular lesions in a patient with gamma3 heavy-chain deposition disease. Clin Nephrol. 2008;69:383–6.PubMedCrossRef Soma J, Tsuchiya Y, Sakuma T, Sato H. Clinical remission and histopathological resolution of nodular lesions in a patient with gamma3 heavy-chain deposition disease. Clin Nephrol. 2008;69:383–6.PubMedCrossRef
31.
go back to reference Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMed Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMed
32.
go back to reference Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M, Immunopathology Group, Italian Society of Nephrology. Renal involvement in systemic amyloidosis—an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22:1608–18.PubMedCrossRef Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M, Immunopathology Group, Italian Society of Nephrology. Renal involvement in systemic amyloidosis—an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22:1608–18.PubMedCrossRef
33.
go back to reference Komatsuda A, Maki N, Wakui H, Ohtani H, Hatakeyama T, Yasuda T, Nakamoto Y, Imai H, Sawada K. Development of systemic λ-light chain amyloidosis in a patient with γ-heavy chain deposition disease during long-term follow-up. Nephrol Dial Transplant. 2005;20:434–43.PubMedCrossRef Komatsuda A, Maki N, Wakui H, Ohtani H, Hatakeyama T, Yasuda T, Nakamoto Y, Imai H, Sawada K. Development of systemic λ-light chain amyloidosis in a patient with γ-heavy chain deposition disease during long-term follow-up. Nephrol Dial Transplant. 2005;20:434–43.PubMedCrossRef
Metadata
Title
Heavy chain deposition disease: an overview
Authors
Yuji Oe
Jun Soma
Hiroshi Sato
Sadayoshi Ito
Publication date
01-12-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0812-x

Other articles of this Issue 6/2013

Clinical and Experimental Nephrology 6/2013 Go to the issue

Images in Nephrology

Polycystic horseshoe kidney

Acknowledgment

List of referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.